More research is also needed to test new potential vaccine antigens such as cholinesterases regulating the neurotransmission of Schistosoma (184), or new tegumental proteins identified by microarray and other modern technologies (178, 185189), and more potent adjuvants targeting specific parts of the innate immune system to tailor a protective immune response for lead schistosome vaccine candidates with the long-term aim to achieve high levels of worm reduction and ultimately elimination of this terrible disease
Risk management includes starting with low doses, monitoring our symptoms, and not using Melanotan if we have a history of skin cancer or unusual moles
(no photo available) 96 tests $974 KT-65892 Primary hepatic carcinoma ELISA Kit (PHC), Human For quantitative detection in human samples
Fisher M, VandenBranden M, Findlay K, Burchell B, Thummel K, Hall S, Wrighton SA: Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank
